- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03399539
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Phase I Clinical Trial of Venetoclax (ABT-199) in Combination With Ixazomib and Dexamethasone for Patients With Relapsed Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of venetoclax in combination with ixazomib citrate (ixazomib) and dexamethasone in patients with relapsed multiple myeloma (MM). (Phase 1)
SECONDARY OBJECTIVES:
I. To describe toxicities associated with venetoclax, in combination with ixazomib and dexamethasone in patients with relapsed MM. (Phase 1)
TERTIARY OBJECTIVES:
I. To explore levels of BCL-2 family member proteins (BCL-2, BCL-x, MCL-1) on bone marrow biopsies using ribonucleic acid sequencing (RNASeq) and immunohistochemistry.
OUTLINE: This is a phase I, dose-escalation study of venetoclax followed by a phase II study.
Patients receive venetoclax orally (PO) daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 or 6 months for 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Rogel Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Siteman Cancer Center at Washington University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Phase 1: Relapsed MM with at least one prior line of therapy and should have received a proteasome inhibitor and an immunomodulatory drug
- Phase 2: 1-3 prior lines of therapy and should have received a proteasome inhibitor and an immunomodulatory drug
- Obtained =< 14 days prior to registration: Calculated creatinine clearance (using Cockcroft-Gault equation) >= 30 mL/min
- Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/uL (without growth factor support)
- Obtained =< 14 days prior to registration: Un-transfused platelet count >= 75000/uL (>= 50,000/uL if marrow plasma cells [PC]% > 50%)
- Obtained =< 14 days prior to registration: Hemoglobin >= 8.0 g/dL
- Obtained =< 14 days prior to registration: Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
- Obtained =< 14 days prior to registration: Alkaline phosphatase =< 750 U/L
- Expansion cohort only: Plasma cell fluorescence in situ hybridization (FISH) test demonstrating presence of t(11;14)
Measurable disease of multiple myeloma as defined by at least ONE of the following:
- Serum monoclonal protein >= 1.0 g/dL
- > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis
- Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
- Provide written informed consent
- Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
Willing to follow strict birth control measures as suggested by the study
Female patients: If they are of childbearing potential, must agree to one of the following:
- Practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
Male patients: even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:
- Agree to practice effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug, OR
- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject; (periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception)
- Life expectancy >= 12 weeks
- Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
- Willing to provide research bone marrow aspirate specimen
Exclusion Criteria:
- Diagnosed or treated for another malignancy =< 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; NOTE: Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Other co-morbidity which would interfere with patient's ability to participate in trial, e.g. uncontrolled infection, uncompensated heart or lung disease
Other concurrent chemotherapy or any ancillary therapy considered investigational
- NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatment
- Peripheral neuropathy >= grade 2 on clinical examination or grade 1 with pain during the screening period
- Major surgery =< 14 days prior to study registration
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject?s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
- Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies) or active hepatitis
- Administration of a strong or moderate CYP3A inhibitor or inducer =< 14 days prior to registration
- Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
- Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
- Failure to have fully recovered (i.e., =< grade 1 toxicity) from the reversible effects of prior chemotherapy
- Radiotherapy =< 14 days prior to registration; Note: If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib
- Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
- Previous treatment with ixazomib, or participated in a blinded study with ixazomib
- Live-virus vaccines =< 28 days prior to registration
- Heart failure > New York Heart Association (NYHA) class II
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (venetoclax, ixazomib citrate, dexamethasone)
Patients receive venetoclax PO daily on days 1-28, ixazomib citrate PO once weekly on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22 for courses 1-12.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given PO
Other Names:
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) of venetoclax in combination with ixazomib and dexamethasone (Phase 1)
Time Frame: Up to 28 days
|
Defined as the dose level below the lowest dose that induces dose-limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients).
Will be examined in an exploratory and hypothesis-generating fashion.
|
Up to 28 days
|
Overall survival
Time Frame: Time from registration to death due to any cause, assessed up to 3 years
|
The distribution of overall survival will be estimated using the method of Kaplan-Meier.
|
Time from registration to death due to any cause, assessed up to 3 years
|
Progression-free survival
Time Frame: Time from registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 3 years
|
The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.
|
Time from registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 3 years
|
Rate of confirmed response defined as a patient who has achieved an stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) on two consecutive evaluations (Phase 2)
Time Frame: Up to 3 years
|
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.
Ninety-five percent confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
|
Up to 3 years
|
Rate of confirmed response in patients with t(11;14) translocation
Time Frame: Up to 3 years
|
Will be estimated by the number of patients with a confirmed sCR, CR, VGPR, or PR divided by the total number of evaluable patients with t(11;14) translocation.
Exact binomial 95% confidence intervals for the true success proportion will be calculated.
|
Up to 3 years
|
Rate of CR defined as the number of patients with an sCR or CR divided by the total number of evaluable patients
Time Frame: Up to 3 years
|
Exact binomial 95% confidence intervals for the true success proportion will be calculated.
|
Up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 3 years
|
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns.
Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Shaji Kumar, M.D., Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dermatologic Agents
- Glycine Agents
- Dexamethasone
- Dexamethasone acetate
- BB 1101
- Venetoclax
- Ixazomib
- Glycine
- Ichthammol
Other Study ID Numbers
- MC168C (Other Identifier: Mayo Clinic)
- NCI-2017-02456 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 16-008629 (Other Identifier: Mayo Clinic Institutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Plasma Cell Myeloma
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | PlasmacytosisUnited States
-
Mayo ClinicActive, not recruitingPlasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell MyelomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Mayo ClinicCompletedPlasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Roswell Park Cancer InstituteBristol-Myers SquibbActive, not recruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer CenterThe Leukemia and Lymphoma Society; Juno Therapeutics, Inc., a Bristol-Myers...TerminatedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States